Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Thrombotic Microangiopathies, Hemolytic ...
Phase Not Applicable
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the etiological factor and this type of TMA is classified, according to the current nomenclature, as primary atypical hemolytic uremic syndrome (HUS). Half the patients with primary atypical HUS present with rare variants in complement genes, although coexisting conditions are often needed for the TMA to become manifest. In patients with secondary atypical HUS, certain coexisting conditions appear to drive the disease and treatment should target the underlying condition to remit the TMA. Recently, the investigators demonstrated, by using a novel in-house developed functional endothelial cell-based test, that complement dysregulation and overactivation is the dominant cause of disease and its sequelae in a subset of patients with secondary atypical HUS, having impact on treatment and prognosis. The investigators did first prove this concept in patients presenting with TMA and hypertensive emergency. A prospective study is needed to further corroborate these findings along the spectrum of TMA. The investigators hypothesize that their functional endothelial cell-based test, the so-called "HMEC" test, can better categorizes the TMA into different groups with potential therapeutic and prognostic implications. Thus, paving the road to the ultimate goal of precision medicine.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The prevalence of complement-mediated TMA along the spectrum of TMA (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-08-11
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht University Medical Center
Principal Investigators:
  • Pieter van Paassen, MD, PhD (PRINCIPAL_INVESTIGATOR) - Maastricht University Medical Center
Contact Information
Study Contact:
Sjoerd A.M.E.G. Timmermans, MD, PhD
+31(0)433871198
sjoerd.timmermans@mumc.nl
Daan P.C. van Doorn, MD
+31(0)433871198
daan.vandoorn@maastrichtuniversity.nl
Sjoerd A.M.E.G. Timmermans, MD, PhD
+31(0)433871198
sjoerd.timmermans@mumc.nl
Maastricht University Medical Center
Interventions
N/A
Study Locations (1 sites)
Maastricht University Medical Center, Maastricht, Limburg 6229HX Netherlands
Eligibility Criteria
Inclusion Criteria: * Males or females at least 18 years of age; * Have acute kidney injury, defined as estimated GFR \<45 mL/min/1.73m2; * Have documented TMA either on peripheral blood, defined as Coombs negative microangiopathic hemolytic anemia (hematocrit \<30%, hemoglobin \<6.5 mmol/L \[\<10 g/dL\], lactate dehydrogenase \>500 U/L, and either schistocytes on peripheral blood smear or undetectable haptoglobin), and platelets \<150,000 per µL, or kidney biopsy; * Have primary atypical HUS or a coexisting condition linked to complement dysregulation: * Hypertensive emergency, defined as SBP/DBP of \>180/120 mmHg and impending organ damage secondary to hypertension (at least one of the following: neurologic disease, hypertensive retinopathy grade III and/or IV, left ventricular hypertrophy); OR * Pregnancy, including 12 weeks postpartum; OR * Kidney donor recipient; OR * Systemic auto-immune disease associated with TMA, including systemic sclerosis, systemic lupus erythematosus, anti-phospholipid syndrome; * Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures. Exclusion Criteria: * Have secondary causes of hypertensive emergency, including renovascular hypertension, Cushing syndrome, aldosteronism, pheochromocytoma, thyroid disease; * Have a nephropathy not related to thrombosis on kidney biopsy; * Have ADAMTS13 deficiency, defined as ADAMTS13 activity \<10%; * Have a positive stool culture for Shiga toxin producing bacteria; * Have positive serologic test for viral infections, including HIV and CMV; * Have a history of malignant disease, excluding non-melanoma skin cancer; * Have a history of bone marrow or solid organ transplantation, excluding kidney transplantation; * Received at least one of the following agents: chemotherapeutics, sirolimus, anti-VEGF agents; * Have a history of recent past exposure to illicit drug(s).
Conditions Diabetes Mellitus, Neuropathy, Neuropath...
Phase Not Applicable
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to assess the effect Spinal Cord Stimulators have toward improving vascular changes of diabetes mellitus in patients eligible for SCS placement based on their condition of painful diabetic neuropathy; we will evaluate improving their disability and quality of life, improving micro-circulatory changes induced by Diabetes Mellitus (DM), improving macro-circulatory changes induced by DM and improving arterial stiffness of the vessels of the lower extremity.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Improve vascular changes (6 Weeks)
  • Vascular improvement on lower extremities with the Ankle Brachial Index (ABI) (6 weeks)
  • Vascular improvement on lower extremities with the Toe Brachial Index (TBI) (6 Weeks)
  • Vascular improvement on lower extremities with the Doppler Flowmetry (6 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-01-27
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Chicago
Principal Investigators:
  • Magdalena Anitescu, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Chicago
Contact Information
Study Contact:
Magdalena Anitescu, MD, PhD
(773) 834-5234
manitescu@dacc.uchicago.edu
Al McAuley, BS
773-834-3274
amcauley1@bsd.uchicago.edu
Magdalena Anitescu, MD, PhD
7738345234
MAnitescu@dacc.uchicago.edu
University of Chicago Medical Center
Interventions
N/A
Study Locations (1 sites)
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients with DM type 2 of more than 1-year duration 2. DM stage 3 or less 3. Patients ≥18 years of age 4. Refractory painful diabetic peripheral neuropathy of the lower extremities 5. ABI index \<0.9 Exclusion Criteria: 1. Patients on anticoagulants 2. Patients with active infections 3. Patients with HbA1\>10 4. Psychiatric disorders and cognitive dysfunctions 5. Illicit Drug Usage 6. Patients on dialysis 7. BMI\>35.0 8. Surgery within the last 30 days 9. Ulcer of the lower extremities 10. Calcification of the peripheral arteries
Conditions Vasopressin Deficiency
Phase PHASE1
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B). Following a screening visit to determine eligibility, participants will return for three main study visits in Part A. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior. In Part A, thirty participants will be equally randomized to one of six possible groups: 1. 6 IU oxytocin - 24 IU oxytocin - placebo 2. 6 IU oxytocin - placebo - 24 IU oxytocin 3. 24 IU oxytocin - 6 IU oxytocin - placebo 4. 24 IU oxytocin - placebo - 6 IU oxytocin 5. placebo - 6 IU oxytocin - 24 IU oxytocin 6. placebo - 24 IU oxytocin - 6 IU oxytocin Following completion of the Part A crossover portion of the study, in Part B participants may also choose to continue participation in an optional, randomized, double-blind, placebo-controlled substudy of intranasal oxytocin 6 IU or placebo three times a day for two weeks, followed by assessments of emotional behavior.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Intranasal Oxytocin (IN-OXT) — 6 IU single dose
  • Drug: Intranasal Oxytocin (IN-OXT) — IN-OXT 6 IU three times a day for 2 weeks
  • Drug: Placebo — Intranasal placebo three times a day for 2 weeks
  • Drug: Intranasal Oxytocin (IN-OXT) — 24 IU single dose
  • Drug: Placebo — placebo single dose

Primary Outcomes

  • Dot-probe task - anxious behavior between low dose oxytocin and placebo (20 minutes following intervention at each main visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-09-10
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Elizabeth Austen Lawson
Collaborators: Tonix Pharmaceuticals, Inc.
Principal Investigators:
  • Elizabeth A Lawson, MD, MMSc (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Francesca Galbiati, MD
(617) 726-3870
FGALBIATI@BWH.HARVARD.EDU
Elisa Asanza, MSN, MPH
617-726-3870
easanza@mgh.harvard.edu
Francesca Galbiati, MD
(617) 726-3870
fgalbiati@bwh.harvard.edu
Massachusetts General Hospital, Neuroendocrine Unit
Interventions
  • Drug: Intranasal Oxytocin (IN-OXT) — 6 IU single dose
  • Drug: Intranasal Oxytocin (IN-OXT) — IN-OXT 6 IU three times a day for 2 weeks
  • Drug: Placebo — Intranasal placebo three times a day for 2 weeks
  • Drug: Intranasal Oxytocin (IN-OXT) — 24 IU single dose
  • Drug: Placebo — placebo single dose
Study Locations (1 sites)
Massachusetts General Hospital, Neuroendocrine Unit, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 and above * Arginine-vasopressin deficiency * Normal FT4 or T4 * Normal serum/plasma sodium * Stable hormone replacement Exclusion Criteria: * Active substance use disorder within the last 6 months * History of psychosis * Suicidal behavior and/or active suicidal ideation with plan and/or intent, e.g., suicidal ideation of type 4 or type 5 as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS), in the last month * Medication changes within 4 weeks of enrollment or planned medication changes during the study * History of chronic nasal obstruction or local pathology in nostril pathway which, in the opinion of the investigator, would prevent appropriate nasal administration of the study drug. * History of cardiac disease, including arrhythmias, coronary heart disease, coronary artery spasms, valvular heart disease, hypertrophic cardiomyopathy (hypertension is not exclusionary) * History of chronic kidney disease stage III and above * History of liver cirrhosis * Pregnancy or breastfeeding within the last 8 weeks * Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only) * Any significant illness, condition, drug or medical device that the Investigator determines could interfere with study participation, data collection, or safety
Conditions Triple Negative Breast Cancer, Vitamin D...
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation, including an observational arm to describe response in patients who are not deficient. Investigators hypothesize that vitamin D supplementation during neoadjuvant chemotherapy in operable triple negative breast cancer patients with vitamin D deficiency will increase the rate of pathologic complete response chain reaction to that of vitamin D sufficient patients based on historical controls.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Standard of Care Neoadjuvant Chemotherapy (NAC) — Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion. Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.
  • Dietary Supplement: Vitamin D3 — Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
  • Other: Drug Diary — Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.

Primary Outcomes

  • Number of Pathologic Complete Response (pCR) in Vitamin D Supplementation Group (Up to 22 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-10-22
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Emily H Douglas, MD (PRINCIPAL_INVESTIGATOR) - Wake Forest University Health Sciences
Contact Information
Study Contact:
Study Coordinator
336-716-5772
Brandy.Baker@advocatehealth.org
Study Coordinator
336-716-5772
Brandy.Baker@advocatehealth.org
Wake Forest Baptist Health Sciences
Emily H Douglas, MD
Wake Forest Baptist Health Sciences
Interventions
  • Drug: Standard of Care Neoadjuvant Chemotherapy (NAC) — Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion. Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician.
  • Dietary Supplement: Vitamin D3 — Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
  • Other: Drug Diary — Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
Study Locations (1 sites)
Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina 27157 United States
Eligibility Criteria
Inclusion Criteria: * Women or men with histologically confirmed invasive mammary carcinoma. * Known triple negative ER/PR/HER2 receptor status as defined by: * ER and PR less than or equal to 10% and HER2 negative based on one of the following: * IHC 0 or 1+ * IHC 2+ and FISH negative * IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based on the treating investigators discretion (i.e., HER2: CEP17 ratio \< 2.0 or HER2 total copy number \<6) * Patients who plan to undergo neoadjuvant chemotherapy prior to definitive surgical management. Participants are eligible up to 2 weeks after initiating neoadjuvant chemotherapy. * ECOG performance status of 0, 1 or 2. * Age ≥ 18. * The effects of high dose vitamin D on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative). Exclusion Criteria: * Patients with nephrolithiasis within the past year. * Patients with known sarcoidosis. * Patients with corrected calcium \>10.5 mg/dL within 30 days prior to initiation of chemotherapy. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to vitamin D. * Pregnant women are excluded from this study because vitamin D supplementation greater than the recommended daily allowance (RDA) is a pregnancy class C agent with no adequate or well controlled studies in humans. * Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with high dose vitamin D (greater than RDA), women who are breastfeeding are excluded from this study. * Prior treatment for this malignancy including surgery, radiation therapy, chemotherapy, hormonal therapy or investigational agent prior to study entry. * Patients currently taking Vitamin D at a dose of 50,000 International Units (IU) once weekly.
Conditions Cardiovascular Diseases, Hypertension
Phase PHASE4
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Losartan — 50 mg tablets taken orally
  • Drug: Placebo — Tablets taken orally

Primary Outcomes

  • Mean Left Ventricular Ejection Fraction (LVEF) (Baseline, approximately 1 day)
  • Mean Aortic pulse wave velocity (PWV) (Baseline, approximately 1 day)
  • Change in Prevalence of CD14++CD16- (Up to 10 weeks)
  • Change in Mean Peak Oxygen Consumption (VO2 Peak) Level (Up to 10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-03-30
Completion: 2026-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: Flight Attendant Medical Research Institute
Principal Investigators:
  • Mehrdad Arjomandi, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Mehrdad Arjomandi, MD
(415)221-4810
mehrdad.arjomandi@ucsf.edu
Mehrdad Arjomandi, MD
415-221-4810
mehrdad.arjomandi@ucsf.edu
San Francisco Veterans' Affairs Medical Center
Interventions
  • Drug: Losartan — 50 mg tablets taken orally
  • Drug: Placebo — Tablets taken orally
Study Locations (1 sites)
San Francisco Veterans' Affairs Medical Center, San Francisco, California 94121 United States
Eligibility Criteria
Inclusion Criteria: * Must be able to understand and provide informed consent. * Adults \>= 40 years of age. * Must have a history of occupational exposure to secondhand tobacco smoke for at least 5 years such as flight attendants who worked for airlines before the smoking ban on aircrafts went into effect or casino workers who worked at casinos with no smoke-free policies. * Must have never smoked or have a remote history of light smoking defined as follows: * Lifetime smoking history equivalent to \< 1 pack-year and * No smoking history for \>= 20 years at the time of enrollment. Exclusion Criteria: * Inability or unwillingness of a participant to give written informed consent or comply with study protocol. * Subject is pregnant, breast-feeding, or plans to become pregnant. * Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). * Known intolerance to ACE inhibitor or ARB. * History of angioedema. * Conventional indication for ACE inhibitor or ARB (e.g., history of myocardial infarction, known cardiomyopathy). * Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic while standing or sitting. * Known unilateral or bilateral renal artery stenosis higher than 70%. * Renal insufficiency (Creatinine Clearance \<30 mL/min by Cockcroft-Gault calculation). * Current regular use of NSAIDs defined as daily use on 5 or more days of the week for more than one month. * Potassium supplementation or serum potassium level of 5.0 milliequivalents (mEq)/dL or higher at V1. * Current use of a potassium sparing diuretic. * History of clinically overt cardiovascular disease including: stable or unstable angina; chest discomfort and dyspnea with baseline exertion; symptomatic coronary artery disease (as defined by history of abnormal stress test; cardiac catheterization showing \>70% coronary artery stenosis; history of revascularization; pathologic Q waves on EKG); poorly controlled resting hypertension (SBP\>160/ DBP\>95); congestive heart failure (CHF) (as defined by left ventricular ejection fraction (LVEF) \<55%; physical exam findings of CHF; symptomatic pulmonary edema); significant (\>mild) valvular heart disease; congenital heart disease; cardiac arrhythmias including frequent premature atrial or ventricular contractions (\>5 per minute). * History of clinically overt pulmonary disease that may interfere with study procedures, including: greater than mild asthma, COPD, emphysema, chronic interstitial lung disease, and pulmonary hypertension. * Neuromuscular disorders or physical disability to perform exercise testing using an ergometer. * Significant history of recreational drug use other than marijuana as defined by: recreational drug use within the last 30 years of recruitment (or) recreational drug use at a frequency of more than once a month before 30 years. * Marijuana use more than once a week. * Other uncontrolled chronic illnesses which in the judgment of the study physician would interfere with completing study procedures. * Failure to keep screening appointments or other indicators of non-adherence. * Concomitant participation in another interventional study. * Subjects with BMI \<15 or \>40 kg/m2. * MRI Scan Participation Exclusion Criteria - The participants will be excluded from the MRI portion of the study if they have a metallic object embedded or implanted in their body that is incompatible with Magnetic Resonance (MR) scanning, including MR incompatible pacemaker or defibrillator.
Conditions Breast Cancer, Residual
Phase Not Applicable
Enrollment 999
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Procedure: chemotherapy or endocrine therapy for breast cancer — Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.

Primary Outcomes

  • Generate patient derived xenografts (PDX) and organoids from breast cancer patients with residual disease after neoadjuvant therapy (Up to 12 months until death or a maximum of 20 years post registration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-01-13
Completion: 2042-01-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 999 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Judy C. Boughey, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
  • Matthew P. Goetz, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic
Judy C. Boughey, M.D.
Mayo Clinic
Interventions
  • Procedure: chemotherapy or endocrine therapy for breast cancer — Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
Study Locations (1 sites)
Mayo Clinic, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy. * Surgically resectable disease following neoadjuvant systemic treatment. * At least one of the following must be true: * Received at least 2 weeks of neoadjuvant endocrine therapy * Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging * Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination * Provide written informed consent. * Willing to return to enrolling institution for breast cancer surgery. * Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic. * Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic. * Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic. Exclusion Criteria: * Ineligible for surgery. * History of prior malignancy \<3 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix).
Conditions Depression, Trauma, Psychological
Phase Not Applicable
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Severe childhood adversity accounts for a large portion of psychiatric illness, and an increased risk for major depressive disorder (MDD). For some individuals, childhood adversity has negative psychological and medical consequences; others preserve mental and physical health despite such experiences (they are resilient). In spite of this, little is known about the neurobiological mechanisms related to childhood adversity, especially oxidative stress abnormalities in the brain. To fill this gap, this study combines functional, structural, and molecular imaging approaches to examine the role of oxidative stress abnormalities related to childhood adversity.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Immuno-oxidative abnormalities (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-02-01
Completion: 2026-06-30
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mclean Hospital
Principal Investigators:
  • Diego Pizzagalli, PhD (PRINCIPAL_INVESTIGATOR) - Mclean Hospital
Contact Information
Study Contact:
Aliza Brown
617-855-2589
abrown98@mclean.harvard.edu
Emma Palermo
617-855-4412
ehpalermo@mclean.harvard.edu
David Crowley
617-855-4432
djcrowley@mclean.harvard.edu
McLean Hospital
Interventions
N/A
Study Locations (1 sites)
McLean Hospital, Belmont, Massachusetts 02478 United States
Eligibility Criteria
Inclusion Criteria: * Females of all races and ethnic origins * Ages from 20 to 32 * Right-handed * Capable of providing written informed consent * Currently unmedicated. Note that this criterion applies at enrollment only, and subjects will be informed that they can continue to be in the study if they begin a new medication after enrollment. * Normal or corrected-to-normal vision and hearing * Fluency in written and spoken English * Absence of first-degree relatives with a history of a psychotic disorder or psychotic symptoms; (adopted individuals are eligible to participate but we will probe about family history in case such information is available to the adopted subject) Exclusion Criteria: * Participants with suicidal ideation where continued study participation is deemed unsafe by the study clinician (these participants will be immediately referred to appropriate clinical treatment) * Pregnant women, or women of childbearing potential who have a positive result on a urine pregnancy test * Failure to meet MRI safety requirements including but not limited to any metal implants or prostheses that cannot be removed, or exposure to shrapnel * Claustrophobia or severe anxiety that might impact participation in neuroimaging * Injury or movement disorder that may make it difficult to lie still in the scanner * Any current recreational/illicit drug use as assessed by a urine drug test (covering cocaine, cannabinoids, opiates, amphetamines, methamphetamines, phencyclidine, MDMA, benzodiazepines, methadone, oxycodone, tricyclic antidepressants, and barbiturates) * Use of drug or herbal supplement for depression (e.g., St. John's Wort or SAMe) of those that could affect stress response * Use of any medication in the 24 hours prior to the Scanning procedure (including antibiotics, asthma inhalants, pain relievers, antihistamines, or over-the-counter medications). * Recent use (within 3 weeks) or any medication that affects blood flow or blood pressure, or which is vasodilating/vasoconstricting * Use of Melatonin within 5 days of the Scanning procedure * Metformin use in the past 6 months (for either clinical care or as part of research) * Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine (hypothyroidism), neurologic, autoimmune disease (such as Lyme, Crohn's), or hematologic disease * Current infectious illness (either transient or chronic); Current episode of allergic reaction or asthma * Hemophilia; Diabetes with poor glucose control; History of chronic migraine (\> 15 days/mo.); History or current diagnosis of dementia * History of seizure disorder * Any history of significant head injury or concussion * Past/current DSM-5 diagnosis of: OCD, ADHD, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders NOS, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, autism or any other pervasive developmental disorder, organic mental disorder, anorexia, binge eating disorder or bulimia (however a history of bulimia or binge eating disorder is allowable if it has been in remission for at least two years) * History of moderate or severe substance or alcohol use disorder; or, mild substance or alcohol use disorder within the last 12 months (with the exception of cocaine or stimulant abuse, which will lead to automatic exclusion). * History of ECT * Patient is clinically unstable, in the judgment of the clinician
Conditions Major Depressive Disorder
Phase PHASE1, PHASE2
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus. This will yield the following groups: MDD-LPS (n=60), MDD-Placebo (n=30), HC-LPS (n=60), HC-placebo (n=30). There are three main aims: to identify immune pathways and neural circuits that respond differently to LPS in MDD vs. HC subjects; (2) to test whether the strength of inflammatory changes induced by LPS is associated with degree of change in anhedonic symptoms and neural circuits in the MDD group, and (3) to identify a biotype of MDD that shows a differential immunological and neurophysiological response to LPS. The main outcome variables are symptoms of anhedonia measured with the Snaith-Hamilton Pleasure Scale (SHAPS), cytokines (Il-6, IL-8, IL-10, and TNF), and BOLD signal change in the neural circuitry mediating interoceptive processing, i.e. the insula and cingulate cortex. The exploratory aim is to determine whether the acute inflammatory response to LPS can predict the clinical course of depression over a period of six months. The main outcome of this component of the study is self-reported depressive symptoms assessed with the QIDS-SR.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Biological: LPS — Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
  • Biological: Saline — 0.9% saline administered as an intravenous bolus

Primary Outcomes

  • Inflammatory response (1.5 hours post infusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-05-15
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laureate Institute for Brain Research, Inc.
Contact Information
Study Contact:
Jonathan Savitz, PhD
918 502 5104
jsavitz@laureateinstitute.org
Jonathan Savitz, PhD
918-502-5104
jsavitz@laureateinstitute.org
Laureate Institute for Brain Research
Interventions
  • Biological: LPS — Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
  • Biological: Saline — 0.9% saline administered as an intravenous bolus
Study Locations (1 sites)
Laureate Institute for Brain Research, Tulsa, Oklahoma 74136 United States
Eligibility Criteria
Inclusion Criteria: Both healthy controls and depressed participants will be required to be in good general health (as evaluated during Visit 1, including EKG) and to be 18-65 years of age. A DSM-V diagnosis of MDD will be made with the MINI International Neuropsychiatric Interview and current symptoms of depression will be measured with the clinician-administered MADRS and the self-report PHQ-9. Depressed participants will be required to have symptoms of depression (i.e. a PHQ-9 score ≥10) and/or a MADRS score of ≥7. Exclusion Criteria: General Exclusion Criteria: * Pregnancy * A history of fainting during blood draws will be evaluated by the clinical team and may be deemed exclusionary. Medical Conditions: * Moderate to severe traumatic brain injury (\>30 min. loss of consciousness or \>24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits. * Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders. * Presence of co-morbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders. * Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk. * Presence of chronic infection that may elevate pro-inflammatory cytokines. * Presence of an acute infectious illness or receipt of a vaccination in the two weeks prior to an experimental session. Psychiatric Disorders: * Current severe suicidal ideation or attempt within the past 12 months. * Psychosis * Bipolar disorder * Substance abuse or dependence within the previous 6 months Contraindications for MRI: * Cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy. * Claustrophobia that is severe enough to preclude MRI scanning. Medications: * Current and/or past regular use of hormone-containing medications (excluding contraceptives) * Use of medications such as oral corticosteroids which may have immunosuppressive effects. * Current use of non-steroid anti-inflammatory drugs that is deemed by the investigators to potentially confound the results of the study (e.g. \> 3 days/week) * Current and/or past regular use of immune modifying drugs that target specific immune responses such as TNF antagonists * Current use of analgesics such as opioids or history of addiction to opioids or other analgesics * Current and/or past regular use of cardiovascular medications, including antihypertensive, antiarrhythmic, anti-anginal, and anticoagulant drugs (does not apply where medications are taken for different purpose e.g. anti-hypertensives for migraine). * Chronic use of antibiotics such as isotretinoin or minocycline because of their potential effects on the microbiome and immune function. * Evidence of recreational drug use from urine test. * Lifetime use of methamphetamine * Inclusion of individuals reporting other types of medications or supplements not listed or considered thus far will be at the discretion of the PI based on their potential to affect immune function, the microbiome, brain function or brain blood flow. Health Factors: * BMI \> 35 because of the effects of obesity on pro-inflammatory cytokine activity * Clinically significant abnormalities on screening laboratory tests * Abnormal EKG * In addition, participants who on arrival to the study, show any of the following symptoms will not be allowed to complete the study: 1. screening supine systolic blood pressure \>140 mmHg or \<100 mmHg 2. screening supine diastolic blood pressure \>90 mmHg or \<60 mmHg 3. 12-lead EKG demonstrating a PR interval \> 0.2 msec QTc \>450 or QRS \>120 msec (Bazett) If the QTc exceeds 450 msec, or QRS exceeds 120 msec, the EKG will be repeated 2 more times and the median value will be used 4. pulse less than 50 beats/minute or greater than 100 beats/minute 5. temperature greater than 99.5 degrees F. Non-English speaking participants: * The majority of the assessments proposed for this study have not been translated from English, thus, non-English speaking volunteers will be excluded.
Conditions Carcinoma Breast, Triple-negative Breast...
Phase PHASE4
Enrollment 1072
Locations 34 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Huaier Granule — The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.

Primary Outcomes

  • 3-year rates of disease-free survival (Start of treatment until 3-year follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-06-18
Completion: 2028-07-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1072 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Collaborators: LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Principal Investigators:
  • Zhimin Shao, PhD (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhimin Shao, PhD
+86-18017312288
zhimingshao@yahoo.com
Liang Huang, PhD
+86-18121299334
fdhlyx@163.com
Jingjie Zhang
The First Affiliated Hospital of Anhui Medical University
Interventions
  • Drug: Huaier Granule — The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
Study Locations (34 sites)
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui China
The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Anhui China
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing Municipality China
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality China
Fujian Cancer Hospital, Fuzhou, Fujian China
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital, Shijiazhuang, Hebei China
The First Affiliates Hospital of Ha'erbin University, Harbin, Heilongjiang China
Henan Provincial People's Hospital, Zhengzhou, Henan China
Eligibility Criteria
Inclusion Criteria: 1. Aged from 18 to 70. 2. Histologically confirmed as breast invasive ductal carcinoma. 3. Molecular typing of breast lesions is triple-negative breast cancer, when the patient had multicentric lesions at the same time, all invasive lesions were confirmed as triple-negative. 4. Regional lymph node metastasis confirmed by postoperative pathology \[except isolated tumor cells ( ITC )\], or tumor response did not achieve pathological complete response (pCR) after neoadjuvant therapy \[neoadjuvant chemotherapy completed at least four cycles, the breast has residual invasive cancer or axillary lymph node metastasis ( except isolated tumor cells ) .\] 5. There was no local recurrence and distant metastasis of the tumor. 6. The time of randomization is during the postoperative adjuvant therapy or within 60 days after the end of the last postoperative adjuvant therapy. 7. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1. 8. Hepatic function and renal function: serum creatinine level ≤ 1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) concentration / alanine aminotransferase (ALT) concentration≤ 2.5 × ULN,total serum bilirubin concentration≤ 1.5 × ULN. 9. Blood routine: neutrophil count ≥ 1.5\*109 / L, platelet count ≥ 100\*109 / L, hemoglobin concentration ≥ 90 g / L (without transfusion). 10. The participants volunteered to join the study with good compliance and signed an informed consent form. Exclusion Criteria: 1. Bilateral breast cancer. 2. Complicated with severe cardiopathy, hepatopathy, nephropathy, endocrine system diseases. According to the researchers' judgement, the comorbidities can cause unacceptable safety risks and affect participants' compliance with research programs. 3. Suffering from malignant tumors other than breast cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) in the past 5 years. 4. Allergic to Huaier granule. 5. Pregnant or lactating women, and those who planning a pregnancy during the study period. 6. Participating in other clinical trials or participated in other clinical studies within 3 months. 7. Patients with a poor compliance, or they are not appropriate for this study because of other reasons considered by the researchers.
Conditions Breast Cancer, Axillary Lymph Node Disse...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

It has been hypothesized that damaged arm lymphatic drainage is associated with the arm lymphedema after axillary lymph node dissection (ALND). However, the majority of breast cancer patients with complete ALND has not suffered from arm lymphedema, which appears to be due to the residual arm lymph nodes that has not been removed in the axillary dissection. With the compensation of the residual arm lymph flow above the level of axillary vein, the arm lymphatic drainage could keep balance and remain normal function. This arm lymphedema prediction model that included the protective factor, the proportion of arm lymph flow above the level of axillary vein, allows intraoperative intervention to be performed for the high-risk group. The arm lymphatics of these distinguished patients would be preserved to eliminate the occurrence of arm lymphedema in this study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Procedure: Axillary surgery based on lymphedema prediction nomogram — Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.

Primary Outcomes

  • Rate of arm lymphedema (Up to 5 years)
  • Rate of locoregional recurrence (Up to 5 years)
  • Rate of distant metastasis (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-12-11
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wuhan University
Principal Investigators:
  • Gaosong Wu, Ph.D. (PRINCIPAL_INVESTIGATOR) - Wuhan University
Contact Information
Study Contact:
Qianqian Yuan, M.D.
13026322297
Yuanqq11@whu.edu.cn
Qianqian Yuan, MD.
+8613026322297
Yuanqq11@whu.edu.cn
Zhongnan Hospital of Wuhan University
Interventions
  • Procedure: Axillary surgery based on lymphedema prediction nomogram — Based on the intraoperative lymphedema prediction nomogram, individualized treatment was recommended to breast cancer patients with different level of risk. For patients with low possibility of developing breast cancer related lymphedema, it was not necessary to preserve arm lymphatics. While the breast cancer patients who were performed mastectomy and ALND with 28 kg/m2 prepared to receive taxane-based chemotherapy, supraclavicular and infraclavicular radiotherapy, according to the established intraoperative nomogram, the proportion of the arm lymph flow above the axillary vein needed to exceed 52%. Otherwise, the arm lymphatics should be identified and preserved.
Study Locations (1 sites)
Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071 China
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older with T1-3 invasive breast cancer; * Clinically node-positive breast cancer, defined as positive on preoperative axillary palpation, ultrasound examination, and computed tomography scan with contrast; * Patients who underwent mastectomy with a positive sentinel lymph node (SLN); * Patients who underwent breast-conserving surgery containing more than two positive SLNs. Exclusion Criteria: * Neoadjuvant chemotherapy; * Previous history of breast cancer.
Conditions Diabetes Mellitus, Type 1, Impaired Hypo...
Phase PHASE3
Enrollment 57
Locations 29 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

Design

Study type: Interventional Phases: Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: VX-880 — Infused into the hepatic portal vein.
  • Biological: VX-017 — Infused into the hepatic portal vein.

Primary Outcomes

  • Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) (From VX-880 infusion to end of study (at least 5 years))
  • Parts B and C: Proportion of Participants who are Insulin Independent with Absence of Severe Hypoglycemic Events (SHEs) (1 year after achieving insulin independence (following VX-880 infusion))
  • Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) (From VX-017 infusion to end of study (at least 5 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-03-29
Completion: 2031-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 57 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vertex Pharmaceuticals Incorporated
Contact Information
Study Contact:
Medical Information
617-341-6777
medicalinfo@vrtx.com
Interventions
  • Biological: VX-880 — Infused into the hepatic portal vein.
  • Biological: VX-017 — Infused into the hepatic portal vein.
Study Locations (29 sites)
City of Hope, Duarte, California 91010 United States
University of California San Francisco, San Francisco, California 94143 United States
UHealth Diabetes Research Institute, Miami, Florida 33136 United States
Northwestern Organ Transplant Center, Chicago, Illinois 60611 United States
University of Chicago, Chicago, Illinois 60637 United States
Johns Hopkins University, Baltimore, Maryland 21287 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
University of Pittsburgh Medical Center Montefiore, Pittsburgh, Pennsylvania 15213 United States
Baylor Scott and White Research Institute, Dallas, Texas 75246 United States
Eligibility Criteria
Key Inclusion Criteria: * Clinical history of T1D with \>=5 years of duration of insulin dependence * At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment * Stable diabetic treatment * Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study Key Exclusion Criteria: -Prior islet cell transplant, organ transplant, or cell therapy Other protocol-defined Inclusion/Exclusion criteria may apply
Conditions Intraabdominal Hypertension, Abdominal C...
Phase Not Applicable
Enrollment 2500
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Device: Accuryn Monitoring System — The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.

Primary Outcomes

  • Urine Output (UO) (30 days)
  • Intra-Abdominal Pressure (IAP) (30 days)
  • Temperature (T) (30 days)
  • Intraabdominal Hypertension (IAH) (30 days)
  • Abdominal Compartment Syndrome (ACS) (30 days)
  • Acute Kidney Injury (AKI) (30 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-12-21
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Potrero Medical
Principal Investigators:
  • Vanessa Moll, MD, PhD (STUDY_DIRECTOR) - Potrero Medical
Contact Information
Study Contact:
Bev Ann Blackwell
256-679-5422
bblackwell@potreromed.com
Ariane Marcus
888-635-7280
amarcus@potreromed.com
Gage Parr, MD
202-715-4000
KPARR@mfa.gwu.edu
George Washington University Hospital
Interventions
  • Device: Accuryn Monitoring System — The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
Study Locations (9 sites)
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
San Francisco VA Medical Center, San Francisco, California 94121 United States
George Washington University Hospital, Washington D.C., District of Columbia 20037 United States
Cleveland Clinic Florida, Weston, Florida 33331 United States
Jewish Hospital / University of Louisville, Louisville, Kentucky 40202 United States
Mission Health Hospital, Asheville, North Carolina 28803 United States
Duke University Hospital, Durham, North Carolina 27710 United States
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina 27157 United States
Cleveland Clinic, Cleveland, Ohio 44195 United States
Eligibility Criteria
Inclusion Criteria: 1. Signed or Verbal Informed Consent as required by IRB (if applicable). 2. Adult (age ≥ 18). 3. Monitored on the Accuryn® Monitoring System during their procedure and ICU stay (for retrospective enrollment). 4. Patient is undergoing cardiac surgical intervention(s). Exclusion Criteria: 1. Known history of advanced chronic kidney disease defined by an estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73m2 within 30 days prior to procedure. 2. The patient is unsuitable for the study, in the opinion of the investigator. This may include vulnerable patient populations such as pregnant women, prisoners ,or those detained in a penal institution.